Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

Hoth Therapeutics, Inc.

Hoth Therapeutics develops innovative treatments aimed at improving patient quality of life. The company focuses on creating impactful and ground-breaking therapies.

Hoth Therapeutics

At Hoth Therapeutics, Inc.  (NASDAQ: HOTH), we strive to develop innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating promising drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate medications that hold immense potential to create breakthroughs and diversify treatment options.

Hoth Therapeutics, Inc

Are you registered for NobleCon? Make sure to catch our CEO, Robb Knie, as he presents at Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference at Florida Atlantic University, College of Business, Executive Education Complex, December 3-5.
ATTENDEE REGISTRATION: https://lnkd.in/eQJf5HS8

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-2.50M -	-7.70M 208.74%	-7.20M 6.58%	-14.31M 98.86%	-11.37M 20.55%	-7.85M 31.01%
depreciation and amortization	1.22K -	1.23K 0.08%	1.04K 14.86%
deferred income tax		-3.66K -	-49.38K 1,247.60%
stock based compensation	143.05K -	2.50M 1,644.26%	737.75K 70.43%	1.32M 79.31%	620.80K 53.07%	216.43K 65.14%
change in working capital	80.46K -	169.64K 110.84%	-131.75K 177.67%	529.92K 502.21%	594.48K 12.18%	-700.75K 217.88%
accounts receivables
inventory
accounts payables	94.36K -	267.36K 183.35%	-151.99K 156.85%	535.34K 452.23%	590.63K 10.33%	-700.75K 218.64%
other working capital	-13.90K -	-97.72K 603.09%	20.24K 120.71%	-5.42K 126.78%	3.85K 170.98%	700.75K 18,115.54%
other non cash items	168.16K -	95K 43.51%	506.96K 433.64%	370.83K 26.85%	858.82K 131.59%	-818.13K 195.26%
net cash provided by operating activities	-2.10M -	-4.95M 135.29%	-6.13M 23.97%	-12.09M 97.13%	-9.30M 23.10%	-8.45M 9.15%
investments in property plant and equipment		-95K -	-167.46K 76.27%	-116.97K 30.15%	-74K 36.74%
acquisitions net			-410K -	116.97K 128.53%
purchases of investments		-800K -	-2.30M 187.50%	-2.56M 11.14%
sales maturities of investments			1.09M -	2.51M 130.11%	1.24M 50.72%
other investing activites			-50K -	-116.97K 133.94%
net cash used for investing activites		-895K -	-1.84M 105.32%	-165.35K 91.00%	1.16M 802.55%
debt repayment
common stock issued	1.19M -	7.45M 528.02%	8.67M 16.35%	17.84M 105.74%	5.99M 66.44%	11.31M 89.05%
common stock repurchased	132.16K -				-10 -
dividends paid
other financing activites	-163.68K -	163 100.10%	56.25K 34,409.20%	359.51K 539.13%	51K 85.81%	2.35K 95.38%
net cash used provided by financing activities	1.15M -	7.45M 545.17%	8.73M 17.11%	18.19M 108.53%	6.04M 66.82%	11.32M 87.49%
effect of forex changes on cash			-15.35K -	-30.56K 99.09%	-9.59K 68.61%	-6.52K 32.05%
net change in cash	-947.82K -	1.61M 269.68%	738.80K 54.06%	5.91M 699.75%	-2.11M 135.70%	2.86M 235.74%
cash at beginning of period	1.23M -	282.62K 77.03%	1.89M 569.05%	2.63M 39.07%	8.54M 224.69%	6.43M 24.71%
cash at end of period	282.62K -	1.89M 569.05%	2.63M 39.07%	8.54M 224.69%	6.43M 24.71%	9.29M 44.55%
operating cash flow	-2.10M -	-4.95M 135.29%	-6.13M 23.97%	-12.09M 97.13%	-9.30M 23.10%	-8.45M 9.15%
capital expenditure		-95K -	-167.46K 76.27%	-116.97K 30.15%	-74K 36.74%
free cash flow	-2.10M -	-5.04M 139.81%	-6.30M 24.96%	-12.21M 93.74%	-9.37M 23.23%	-8.45M 9.87%

NASDAQ:HOTH

Hoth Therapeutics

Last Close

0.86

25/09 14:34

Market Cap

4.91M

Beta: 0.12

Volume Today

93.74K

Avg: 729.84K

PE Ratio

−0.48

PFCF: −0.75

Preview